Cargando…
Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions
Fibrosis accompanies various pathologies, and there is thus an unmet medical need for non-invasive, sensitive, and quantitative methods for the assessment of fibrotic processes. Currently, needle biopsy with subsequent histological analysis is routinely used for the diagnosis along with morphologica...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674214/ https://www.ncbi.nlm.nih.gov/pubmed/38004406 http://dx.doi.org/10.3390/ph16111540 |
_version_ | 1785140775671037952 |
---|---|
author | Eriksson, Olof Velikyan, Irina |
author_facet | Eriksson, Olof Velikyan, Irina |
author_sort | Eriksson, Olof |
collection | PubMed |
description | Fibrosis accompanies various pathologies, and there is thus an unmet medical need for non-invasive, sensitive, and quantitative methods for the assessment of fibrotic processes. Currently, needle biopsy with subsequent histological analysis is routinely used for the diagnosis along with morphological imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). However, none of these imaging techniques are sufficiently sensitive and accurate to detect minor changes in fibrosis. More importantly, they do not provide information on fibrotic activity on the molecular level, which is critical for fundamental understanding of the underlying biology and disease course. Molecular imaging technology using positron emission tomography (PET) offers the possibility of imaging not only physiological real-time activity, but also high-sensitivity and accurate quantification. This diagnostic tool is well established in oncology and has exhibited exponential development during the last two decades. However, PET diagnostics has only recently been widely applied in the area of fibrosis. This review presents the progress of development of radiopharmaceuticals for non-invasive detection of fibrotic processes, including the fibrotic scar itself, the deposition of new fibrotic components (fibrogenesis), or the degradation of existing fibrosis (fibrolysis). |
format | Online Article Text |
id | pubmed-10674214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106742142023-11-01 Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions Eriksson, Olof Velikyan, Irina Pharmaceuticals (Basel) Review Fibrosis accompanies various pathologies, and there is thus an unmet medical need for non-invasive, sensitive, and quantitative methods for the assessment of fibrotic processes. Currently, needle biopsy with subsequent histological analysis is routinely used for the diagnosis along with morphological imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). However, none of these imaging techniques are sufficiently sensitive and accurate to detect minor changes in fibrosis. More importantly, they do not provide information on fibrotic activity on the molecular level, which is critical for fundamental understanding of the underlying biology and disease course. Molecular imaging technology using positron emission tomography (PET) offers the possibility of imaging not only physiological real-time activity, but also high-sensitivity and accurate quantification. This diagnostic tool is well established in oncology and has exhibited exponential development during the last two decades. However, PET diagnostics has only recently been widely applied in the area of fibrosis. This review presents the progress of development of radiopharmaceuticals for non-invasive detection of fibrotic processes, including the fibrotic scar itself, the deposition of new fibrotic components (fibrogenesis), or the degradation of existing fibrosis (fibrolysis). MDPI 2023-11-01 /pmc/articles/PMC10674214/ /pubmed/38004406 http://dx.doi.org/10.3390/ph16111540 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Eriksson, Olof Velikyan, Irina Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions |
title | Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions |
title_full | Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions |
title_fullStr | Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions |
title_full_unstemmed | Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions |
title_short | Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions |
title_sort | radiotracers for imaging of fibrosis: advances during the last two decades and future directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674214/ https://www.ncbi.nlm.nih.gov/pubmed/38004406 http://dx.doi.org/10.3390/ph16111540 |
work_keys_str_mv | AT erikssonolof radiotracersforimagingoffibrosisadvancesduringthelasttwodecadesandfuturedirections AT velikyanirina radiotracersforimagingoffibrosisadvancesduringthelasttwodecadesandfuturedirections |